NewHopeR
Senior Member
- Joined
- Nov 6, 2009
- Member Type
- Student or Learner
- Native Language
- Chinese
- Home Country
- China
- Current Location
- China
Context:
The US Food and Drug Administration’s (FDA) approval of Boehringer Ingelheim’s dabigatran for stroke prevention in patients with atrial fibrillation in October, 2010, was a watershed event for cardiologists. It marked an end to a 50 year hunt for a replacement for warfarin—a widely used but difficult to dose drug—and promised a new era in anticoagulant therapy.
Uptake was swift, and the drug rapidly headed for blockbuster status. But a string of safety flags, including most recently data suggesting the drug increases the risk of heart attacks, have tempered enthusiasm for the direct thrombin inhibitor.
The US Food and Drug Administration’s (FDA) approval of Boehringer Ingelheim’s dabigatran for stroke prevention in patients with atrial fibrillation in October, 2010, was a watershed event for cardiologists. It marked an end to a 50 year hunt for a replacement for warfarin—a widely used but difficult to dose drug—and promised a new era in anticoagulant therapy.
Uptake was swift, and the drug rapidly headed for blockbuster status. But a string of safety flags, including most recently data suggesting the drug increases the risk of heart attacks, have tempered enthusiasm for the direct thrombin inhibitor.
